105 related articles for article (PubMed ID: 29098396)
41. An introduction to male breast cancer for urologists: epidemiology, diagnosis, principles of treatment, and special situations.
Makdissi FBA; Santos SS; Bitencourt A; Campos FAB
Int Braz J Urol; 2022; 48(5):760-770. PubMed ID: 35373955
[TBL] [Abstract][Full Text] [Related]
42. Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits.
Wang B; Wang H; Zhao A; Zhang M; Yang J
BMC Cancer; 2021 May; 21(1):523. PubMed ID: 33964913
[TBL] [Abstract][Full Text] [Related]
43. Breast cancer-related lymphedema and its treatment: how big is the financial impact?
De Vrieze T; Gebruers N; Nevelsteen I; Tjalma WAA; Thomis S; De Groef A; Dams L; Haenen V; Devoogdt N
Support Care Cancer; 2021 Jul; 29(7):3801-3813. PubMed ID: 33236211
[TBL] [Abstract][Full Text] [Related]
44. Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy.
Adehin A; Kennedy MA; Soyinka JO; Alatise OI; Olasehinde O; Bolaji OO
Breast Cancer (Dove Med Press); 2020; 12():123-130. PubMed ID: 33116814
[TBL] [Abstract][Full Text] [Related]
45. Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls.
Liu J; Suresh A; Palettas M; Stephens J; Ganju A; Morgan E; Kassem M; Hou Y; Parwani A; Noonan A; Reinbolt R; VanDeusen J; Sardesai S; Williams N; Cherian M; Tozbikian G; Stover DG; Lustberg M; Li Z; Ramaswamy B; Wesolowski R
Eur J Breast Health; 2020 Jul; 16(3):201-207. PubMed ID: 32656521
[TBL] [Abstract][Full Text] [Related]
46. Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis.
White-Gilbertson S; Lu P; Jones CM; Chiodini S; Hurley D; Das A; Delaney JR; Norris JS; Voelkel-Johnson C
Cancer Med; 2020 May; 9(9):3142-3152. PubMed ID: 32135040
[TBL] [Abstract][Full Text] [Related]
47. Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer.
Wang Y; Chen K; Yang Y; Tan L; Chen L; Zhu L; Su F; Liu X; Li S
Ann Transl Med; 2019 Oct; 7(20):536. PubMed ID: 31807518
[TBL] [Abstract][Full Text] [Related]
48. What are the economic burden and costs associated with the treatment of breast cancer-related lymphoedema? A systematic review.
De Vrieze T; Nevelsteen I; Thomis S; De Groef A; Tjalma WAA; Gebruers N; Devoogdt N
Support Care Cancer; 2020 Feb; 28(2):439-449. PubMed ID: 31656987
[TBL] [Abstract][Full Text] [Related]
49. Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
Eggemann H; Bernreiter AL; Reinisch M; Loibl S; Taran FA; Costa SD; Ignatov A
Br J Cancer; 2019 Feb; 120(3):301-305. PubMed ID: 30655614
[TBL] [Abstract][Full Text] [Related]
50. The effect of training interventions on physical performance, quality of life, and fatigue in patients receiving breast cancer treatment: a systematic review.
Gebruers N; Camberlin M; Theunissen F; Tjalma W; Verbelen H; Van Soom T; van Breda E
Support Care Cancer; 2019 Jan; 27(1):109-122. PubMed ID: 30302542
[TBL] [Abstract][Full Text] [Related]
51. Surgical options for male breast cancer.
Fentiman IS
Breast Cancer Res Treat; 2018 Dec; 172(3):539-544. PubMed ID: 30187168
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Eggemann H; Ignatov A; Smith BJ; Altmann U; von Minckwitz G; Röhl FW; Jahn M; Costa SD
Breast Cancer Res Treat; 2013 Jan; 137(2):465-70. PubMed ID: 23224235
[TBL] [Abstract][Full Text] [Related]
53. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
54. Male breast cancer is not congruent with the female disease.
Fentiman IS
Crit Rev Oncol Hematol; 2016 May; 101():119-24. PubMed ID: 26989051
[TBL] [Abstract][Full Text] [Related]
55. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
56. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
57. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
